A phase i dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors

Anti-Cancer Drugs

Volumn 21, Issue 7, 2010, Pages 716-723

  Saif, Muhammad Wasif ^a   Sellers, Sandra ^b   Diasio, Robert B ^c   Douillard, Jean Yves ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITÉ DE NANTES   (France)

Author keywords

edotecarin; J 107088; maximum tolerated dose; pharmacokinetics; solid tumor; topoisomerase I inhibitor

Indexed keywords

EDOTECARIN; FLUOROURACIL; FOLINIC ACID; LOPERAMIDE;

ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CARCINOID; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM CARCINOMA; DYSESTHESIA; ESOPHAGUS CARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER METASTASIS; LOWER RESPIRATORY TRACT INFECTION; LUNG CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; STEADY STATE; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBAZOLES; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS;

EID: 77954657958     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833cb658     Document Type: Article

References (16)

1. Saif MW, Diasio RB. Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer 2005; 5:27-36.
2. Arakawa H, Morita M, Kodera T, Okura A, Ohkubo M, Morishima H, Nishimura S. In vivo anti-tumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice. Jpn J Cancer Res 1999; 90:1163-1170.
3. Ciomei M, Croci V, Ciavolella A, Ballinari D, Pesenti E. Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model. Clin Cancer Res 2006; 12:2856-2861.
4. Ciomei M, Croci V, Pesenti E, Kodera T, Monden Y, Ciavolella A, et al. Antitumor efficacy of edotecarin in combination with other cytotoxic drugs. Proc Amer Assoc Cancer Res 2004; 45. Abstract # 2099.
5. Cavazos CM, Keir ST, Yoshinari T, Bigner DD, Friedman HS. Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2- hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5Hindolo( 2,3-a)-pyrrolo(3,4-c)-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 2001; 48:250-254.
6. Ciomei M, Croci V, Stellari F, Amboldi N, Giavarini R, Pesenti E. Antitumor activity of edotecarin in breast carcinoma models. Cancer Chemother Pharmacol 2007; 60:229-235.
7. Hurwitz HI, Cohen RB, McGovren JP, Hirawat S, Petros WP, Natsumeda Y, Yoshinari T. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2007; 59: 139-147.
8. Yamada Y, Tamura T, Yamamoto N, Shimoyama T, Ueda Y, Murakami H, et al. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors. Cancer Chemother Pharmacol 2006; 58:173-182.
9. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as fi rst-line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet 2000; 355:1041-1047.
10. Therasse P, Arbuck SG, Eisenhauer EA,Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J NCI 2000; 95:205-216. (Pubitemid 30099779)
11. National Cancer Institute, Cancer Therapy Evaluation Program. CTCAE/ CTC Archive. URL:http://ctep.cancer.gov/reporting/ctc-archive.html:// ctep.cancer.gov/protocoldevelopment/.../ctcv20-4-30-992.pdf
12. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
13. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26: 3523-3529.
14. Shaib W, Lee V, Saif MW. Bolus 5-fluorouracil as an alternative modality to infusion 5-fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity. In Vivo 2009; 23:821-826.
15. Maindrault-Goebel F, Tournigand C, André T, Carola E, Mabro M, Artru P, et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 2004; 15:1210-1214.
16. Nahum K, Shiba D, Padavanija P, Garcia M, Hurwitz H, Mackintosh F, et al. Phase II efficacy and tolerability study of edotecarin (J-107088) in patients with irinotecan-naïve metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003;22. Abstract #1099.